Table 1 Patient demographics and clinical characteristics at index (date of nivolumab initiation)

n, % (95% CI) unless otherwise stated

Age (years)

 Mean (SD)

66.9 (10.0)

67.2 (10.2)

66.2 (9.4)

0.58

 Median (IQR)

66.9 (60.4,74.3)

67.4 (59.8,75.3)

66.2 (60.9,70.9)

Sex

 Female

42, 27.8% (21.3,35.4)

28, 25.7% (18.4,34.6)

14, 33.3% (21.0,48.4)

0.46

 Male

109, 72.2% (64.6,78.7)

81, 74.3% (65.4,81.6)

28, 66.7% (51.6,79.0)

Time from aRCC diagnosis to index date^a(years)

 Mean (SD)

2.6 (2.5)

2.0 (1.8)

4.2 (3.1)

 < 0.01^a

 Median (IQR)

2.0 (0.9,3.6)

1.4 (0.7,2.9)

3.4 (2.0,5.9)

ECOG PS at index^a

 0 (fully active)

49, 32.5% (25.5,40.3)

38, 34.9% (26.6,44.2)

11, 26.2% (15.3,41.1)

0.66

 1 (restrictive)

59, 39.1% (31.7,47.0)

42, 38.5% (29.9,47.9)

17, 40.5% (27.0,55.5)

 2 (off-work)

19, 12.6% (8.2,18.8)

13, 11.9% (7.1,19.3)

6, 14.3% (6.7,27.8)

 3 (limited)

3, 2.0% (0.7,5.7)

3, 2.8% (0.9,7.8)

0, 0.0% (0.0,8.4)

 4 (bedbound)

0, 0.0% (0.0,2.5)

0, 0.0% (0.0,3.4)

0, 0.0% (0.0,8.4)

 Not available^§

21, 13.9%

13, 12%

8, 19.1%

IMDC classification (Heng points) at index^a

 Favourable (0)

23, 15.2% (10.4,21.8)

17, 15.6% (10.0,23.6)

6, 14.3% (6.7,27.8)

0.02^a

 Intermediate (1–2)

60, 39.7% (32.3,47.7)

34, 31.2% (23.3,40.4)

26, 61.9% (46.8,75.0)

 Poor (3)

29, 19.2% (13.7,26.2)

25, 22.9% (16.0,31.7)

4, 9.5% (3.8,22.1)

 Unknown

39, 25.8% (19.5,33.4)

33, 30.3% (22.4,39.5)

6, 14.3% (6.7,27.8)

Histological subtype

 Clear Cell

131, 86.8% (80.4,91.3)

93, 85.3% (77.5,90.8)

38, 90.5% (77.9,96.2)

0.39

 Non-clear cell: papillary

7, 4.6% (2.3,9.3)

6, 5.5% (2.5,11.5)

1, 2.4% (0.1,12.3)

 Non-clear cell: collecting duct

0, 0.0% (0.0,2.5)

0, 0.0% (0.0,3.4)

0, 0.0% (0.0,8.4)

 Non-clear cell: chromophobe

4, 2.6% (1.0,6.6)

4, 3.7% (1.4,9.1)

0, 0.0% (0.0,8.4)

 Non-clear cell: sarcomatoid

2, 1.3% (0.4,4.7)

2, 1.8% (0.5,6.4)

0, 0.0% (0.0,8.4)

 Not available

7, 4.6%

4, 3.6%

3, 7.1%

Prior nephrectomy

 Yes

110, 72.8% (65.3,79.3)

76, 69.7% (60.5,77.6)

34, 81.0% (66.7,90.0)

0.24

Site of metastasis

 Bone

53, 35.1% (27.9,43.0)

37, 33.9% (25.7,43.2)

16, 38.1% (25.0,53.2)

0.77

 Brain

19, 12.6% (8.2,18.8)

15, 13.8% (8.5,21.5)

4, 9.5% (3.8,22.1)

0.67

 Soft tissue

12, 7.9% (4.6,13.4)

9, 8.3% (4.4,15.0)

3, 7.1% (2.5,19.0)

1.00

 Lung

116, 76.8% (69.5,82.8)

85, 78.0% (69.3,84.7)

31, 73.8% (58.9,84.7)

0.74

 Lymph nodes

65, 43.0% (35.4,51.0)

47, 43.1% (34.2,52.5)

18, 42.9% (29.1,57.8)

1.00

 Liver

43, 28.5% (21.9,36.1)

27, 24.8% (17.6,33.6)

16, 38.1% (25.0,53.2)

0.15

 Other

33, 21.9% (16.0,29.1)

20, 18.3% (12.2,26.6)

13, 31.0% (19.1,46.0)

0.14

 None

3, 2.0% (0.7,5.7)

3, 2.8% (0.9,7.8)

0, 0.0% (0.0,8.4)

0.66